GlassScriptPhysician profile
Alexandra Stough
NPI 1790273068
$6,825.64
in general payments reported to CMS, 2019-2025
43 companies · $1,517 in 2025
The $1,517 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $539 · 2022: $1,122 · 2023: $1,963 · 2024: $1,685 · 2025: $1,517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,164.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,553.19 | 2021-2025 | Ubrelvy, Liletta, Qulipta |
| Novo Nordisk INC | $1,399.27 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Gilead Sciences, INC. | $1,170.23 | 2021-2025 | Descovy |
| Pfizer INC. | $345.15 | 2023-2025 | |
| Astellas Pharma US INC | $296.17 | 2024-2025 | Veozah |
| Viiv Healthcare Company | $272.51 | 2022-2025 | Apretude |
| Takeda Pharmaceuticals U.S.A., INC. | $219.32 | 2021-2025 | Trintellix |
| Exeltis, USA INC. | $191.27 | 2022-2025 | Slynd |
| Idorsia Pharmaceuticals US INC | $167.87 | 2023 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $131.06 | 2023-2025 | Breztri, Airsupra |
| Neos Therapeutics, LP | $99.62 | 2022-2024 | Adzenys Xr-Odt |
| Novartis Pharmaceuticals Corporation | $95.86 | 2023-2025 | |
| Incyte Corporation | $74.74 | 2021-2024 | Opzelura |
| Exact Sciences Corporation | $50.85 | 2023 | Cologuard Collection Kit |
| Mayne Pharma Commercial LLC | $48.58 | 2023-2025 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Stough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.